Exchol, 500 mg 50 pcs.

Exchol is a hepatoprotective agent, has a choleretic effect.

Limits the synthesis of cholesterol in the liver, its absorption in the intestine and its concentration in the bile, increases the solubility of cholesterol in the biliary system, stimulates the formation and excretion of bile.

Decreases lithogenicity of bile, increases the content of bile acids in it; causes increased gastric and pancreatic secretion, increases lipase activity, has hypoglycemic effect.

Causes partial or complete dissolution of cholesterol stones when enteral administration, reduces the saturation of bile with cholesterol, which promotes the mobilization of cholesterol from gallstones.

It has immunomodulatory effect, influences immunological reactions in the liver: decreases the expression of some antigens on the membrane of hepatocytes, affects the number of T-lymphocytes, interleukin-2 formation, decreases the number of eosinophils.

Indications

Gallstone disease, Liver cirrhosis, Hepatitis, Constipation, Biliary dyskinesia, Reflux esophagitis, Colic, Pain, Alcoholism, Liver damage

• Chronic active hepatitis;
• toxic (incl. ч.
• drug-induced liver disease;
• alcoholic liver disease;
• non-alcoholic steatohepatitis;
• primary biliary cirrhosis of the liver;
• cystic fibrosis (cystic fibrosis) of the liver;
• dyskinesia of the biliary tract;
• biliary reflux gastritis and reflux esophagitis.

.

Active ingredient

Ursodeoxycholic acid

Composition

Filmed film-coated tablets white or almost white, oval, with a rib; cross-section is white or almost white.

1 tablet ursodeoxycholic acid 500 mg

Auxiliary substances:

calcium hydrophosphate dihydrate – 40 mg,

calcium stearate – 7 mg,

sodium carboxymethyl starch – 28 mg,

potato starch – 33.5 mg,

mannitol – 58 mg,

macrogol (polyethylene glycol 4000) – 3.5 mg,

povidone K30 – 30 mg.

Composition of the film coating:

Opadray white – 20 mg (hypromellose (hydroxypropyl methylcellulose) – 6.75,

Hyprolose (hydroxypropyl methylcellulose) – 6.75,

talc – 4 mg,

titanium dioxide – 2.5 mg).

How to take, the dosage

Intravenously, without chewing, with plenty of water.

Diffuse liver diseases, gallstone disease (cholesterol gallstones and biliary sludge): Exxol® is administered continuously for a long time (from several months to several years) in a daily dose from 10 mg/kg to 12-15 mg/kg (2-5 capsules).

The duration of intake for dissolution of stones is up to complete dissolution, plus another 3 months to prevent recurrence of stone formation. In diffuse liver diseases a daily dose of Exxol® is divided into 2-3 doses, the capsules are taken with food. In cholelithiasis the whole daily dose is taken once at night.

Biliary reflux gastritis and reflux esophagitis: The drug is prescribed in doses of 250 mg/day (1 capsule), before bedtime. The course of treatment is from 10-14 days to 6 months, if necessary – up to 2 years.

After cholecystectomy, to prevent recurrent cholelithiasis: the recommended dose is 250 mg 2 times a day for several months.

Toxic, drug-induced liver damage, alcoholic liver disease and biliary atresia: the daily dose is set at the rate of 10-15 mg/kg in 2-3 doses. Duration of therapy is 6-12 months or more.

Primary biliary cirrhosis: the drug is prescribed at the rate of 10-15 mg/kg/day (if necessary – up to 20 mg/kg) in 2-3 times. Duration of therapy is from 6 months to several years.

Primary sclerosing cholangitis: 12-15 mg/kg/day (up to 20 mg/kg) in 2-3 times. Duration of therapy – from 6 months to several years.

Non-alcoholic steatohepatitis: 13-15 mg/kg/day in 2-3 doses. Duration of therapy – from 6 months to several years.

Mucoviscidosis: the dose is set at the rate of 20-30 mg/kg/day (up to 20 mg/kg) in 2-3 doses. Duration of therapy is from 6 months to several years. For children over 3 years old the dose is prescribed individually at the rate of 10-20 mg/kg/day.

Interaction

Antacids containing aluminum and ion exchange resins (colestyramine) reduce absorption of the drug.

Hypolipidemic drugs (especially clofibrate), estrogens, neomycin or progestins increase bile cholesterol saturation and may decrease the ability to dissolve cholesterol bile concretions.

Special Instructions

For successful dissolution, it is necessary that the stones are pure cholesterol stones not more than 15-20 mm in size, the gallbladder is not more than half filled with stones and the biliary tract fully preserved its function.

When prescribing for dissolution of gallstones it is necessary to control the activity of “hepatic” transaminases and alkaline phosphatase (ALP), gamma-glutamintransferase (GGT), bilirubin concentration. Cholecystography should be performed every 4 weeks during the first 3 months of treatment, and every 3 months thereafter. Control of treatment efficacy should be carried out every 6 months during ultrasound investigation during the first year of therapy.

If elevated values persist, the drug should be discontinued. After complete dissolution of concrements it is recommended to continue the use for at least 3 months in order to promote dissolution of the remaining concrements which are too small to be detected and for prevention of recurrence of calculi formation.

If within 6-12 months after the beginning of therapy partial dissolution of the concrements has not occurred, it is unlikely that the treatment will be effective. Detection of an unvisualized gallbladder during treatment is an indication that complete dissolution of the concrements has not occurred and treatment should be discontinued.

Contraindications

• Hypersensitivity;
• X-ray-positive (high calcium) gallstones;
• functional gallbladder;
• biliary-gastric fistula;
• acute cholecystitis;
• acute cholangitis;
• decompensated liver cirrhosis;
• acute infectious diseases of the gallbladder, bile ducts and intestine;
• explicit hepatic and/or renal insufficiency;
• biliary tract obstruction;
• empyema of the gallbladder;
• children under 3 years of age.

Cautious: Children aged 3 to 4 years, as swallowing the capsules may be difficult.

Side effects

Back pain, nausea, vomiting, diarrhea (may be dose-dependent), constipation, transient (transient) increase in the activity of “liver” transaminases, allergic reactions, rarely – calcification of gallstones, exacerbation of pre-existing psoriasis, alopecia.

Overdose

No cases of overdose have been identified. In case of overdose symptomatic treatment is administered.

Similarities

Ursofalk, Ursosan, Urdoxa, Ursoliv, Ursodez, Grinterol, Urcevel, Ursodeoxycholic acid